WO2002012892A3 - Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke - Google Patents

Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke Download PDF

Info

Publication number
WO2002012892A3
WO2002012892A3 PCT/US2001/024248 US0124248W WO0212892A3 WO 2002012892 A3 WO2002012892 A3 WO 2002012892A3 US 0124248 W US0124248 W US 0124248W WO 0212892 A3 WO0212892 A3 WO 0212892A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
biomarkers
tia
blood tests
multiple panel
Prior art date
Application number
PCT/US2001/024248
Other languages
French (fr)
Other versions
WO2002012892A2 (en
Inventor
Svetlana A Dambinova
Original Assignee
Svetlana A Dambinova
Cis Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svetlana A Dambinova, Cis Biotech Inc filed Critical Svetlana A Dambinova
Priority to AU2001280996A priority Critical patent/AU2001280996A1/en
Publication of WO2002012892A2 publication Critical patent/WO2002012892A2/en
Publication of WO2002012892A3 publication Critical patent/WO2002012892A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
PCT/US2001/024248 2000-08-04 2001-08-02 Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke WO2002012892A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001280996A AU2001280996A1 (en) 2000-08-04 2001-08-02 Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63274900A 2000-08-04 2000-08-04
US09/632,749 2000-08-04
US30129701P 2001-06-27 2001-06-27
US60/301,297 2001-06-27

Publications (2)

Publication Number Publication Date
WO2002012892A2 WO2002012892A2 (en) 2002-02-14
WO2002012892A3 true WO2002012892A3 (en) 2003-07-31

Family

ID=26972282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024248 WO2002012892A2 (en) 2000-08-04 2001-08-02 Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke

Country Status (2)

Country Link
AU (1) AU2001280996A1 (en)
WO (1) WO2002012892A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896872B2 (en) 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
GB0203768D0 (en) * 2002-02-18 2002-04-03 Univ Geneve Diagnostic method for stroke
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
DE602006018145D1 (en) 2005-06-13 2010-12-23 Cis Biotech Inc METHOD FOR THE DIAGNOSIS AND TREATMENT ON NR2-PEPTIDES BASED ON CEREBROVASCULAR EVENTS
US20090258824A1 (en) * 2005-07-29 2009-10-15 Ashe Karen H Amyloid beta receptor and uses thereof
EP2152907A1 (en) 2007-05-01 2010-02-17 The Regents of the University of California Methods for diagnosing ischemia
EP2593566B1 (en) * 2010-07-14 2018-01-24 The Regents of The University of California Biomarkers for diagnosis of transient ischemic attacks
WO2012009567A2 (en) 2010-07-15 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of stroke and its causes
WO2012121978A2 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Biomarkers for the diagnosis of lacunar stroke
GB2497138A (en) 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
WO2013103781A1 (en) 2012-01-07 2013-07-11 The Regents Of The University Of California Biomarkers for diagnosing ischemia
JP2015512036A (en) * 2012-02-15 2015-04-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Means and methods for assessing neurotoxicity
JP6042968B2 (en) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム How to treat Parkinson's disease
WO2014160431A1 (en) * 2013-03-13 2014-10-02 Health Diagnostic Laboratory, Inc. Method of determining prior history of ischemic stroke for current risk evaluation and therapy guidance
GB201309928D0 (en) 2013-06-04 2013-07-17 Randox Lab Ltd Method
GB201619823D0 (en) 2016-11-23 2017-01-04 Randox Laboratories Ltd And Teoranta Randox GFAP accumulating stroke
RU2668534C1 (en) 2017-07-18 2018-10-01 Общество с ограниченной ответственностью "ДРД" Diagnostic kit of reagents for detecting chronic pathologies of the brain of ischemic genesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUSEV E I ET AL: "Investigation of the level of autoantibodies to glutamate receptors in blood serum of patients in acute period of ischemic stroke.", ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S. S. KORSAKOVA, vol. 96, no. 5, 1996, pages 68 - 72, XP002212398 *
GUSEV E I ET AL: "Neuroprotective effects of glycine for therapy of acute ischaemic stroke.", CEREBROVASCULAR DISEASES (BASEL, SWITZERLAND) SWITZERLAND 2000 JAN-FEB, vol. 10, no. 1, January 2000 (2000-01-01), pages 49 - 60, XP002212399, ISSN: 1015-9770 *
HESS S D ET AL: "CLONING AND FUNCTIONAL CHARACTERIZATION OF HUMAN HETEROMERIC N-METYL-D-ASPARTATE RECEPTORS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 278, no. 2, 1 August 1996 (1996-08-01), pages 808 - 816, XP000676640, ISSN: 0022-3565 *
MELDRUM B S: "Glutamate as a neurotransmitter in the brain: review of physiology and pathology.", THE JOURNAL OF NUTRITION. UNITED STATES APR 2000, vol. 130, no. 4S Suppl, April 2000 (2000-04-01), pages 1007S - 15S, XP001097318, ISSN: 0022-3166 *
MONYER H ET AL: "Heteromeric NMDA receptors: molecular and functional distinction of subtypes.", SCIENCE. UNITED STATES 22 MAY 1992, vol. 256, no. 5060, 22 May 1992 (1992-05-22), pages 1217 - 1221, XP001093645, ISSN: 0036-8075 *
SKOROMETS ALEXANDER A ET AL: "Autoantibodies to NMDA-receptor fragment in patients with ischemic stroke.", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 150, no. SUPPL., 1997, XVI World Congress of Neurology;Buenos Aires, Argentina; September 14-19, 1997, pages S280, XP001098449, ISSN: 0022-510X *

Also Published As

Publication number Publication date
AU2001280996A1 (en) 2002-02-18
WO2002012892A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
WO2002012892A3 (en) Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke
DK1766400T3 (en) Procedure for performing whole blood assays
EP1359417A3 (en) Devices and methods for analyte concentration determination
EP1318399A3 (en) Passive sample detection to initiate timing of an assay
WO2003106964A3 (en) High throughput methods and devices for assaying analytes in a fluid sample
WO2003066906A3 (en) Diagnostic microarray and method of use thereof
EP0987550A3 (en) Analytical test device and method of use
WO2003001964A3 (en) Measurement testing of blood specimens
WO2003102018A3 (en) Methods for quantitative proteome analysis of glycoproteins
EP2149792A3 (en) Sample analyzing method and sample analyzing device
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
ES2162361T3 (en) IMPROVED METHODS, KITS AND REAGENTS FOR THE SAMPLE OF DEFECTS OF THE BLOOD COAGULATION.
WO2004089187A3 (en) Caries risk test for predicting and assessing the risk of disease
WO2005001058A3 (en) Identification of biomarkers for liver toxicity
KR101946884B1 (en) Method for diagnosing Behcet's disease by using metabolomics
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
AU2003260457A1 (en) A method and kit for the quantitative and/or qualitative detection of components in a sample
DE69808930D1 (en) LIVER FUNCTION TEST
EP1288647A3 (en) Spectroscopic test system based on microcapillaries
DE60333876D1 (en) Methods for detecting analytes in samples
ATE449868T1 (en) METHODS, TEST SETS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING TARGET SEQUENCES
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
WO2002066982A3 (en) Analysis of modification and demodification of proteins with ubiquitin-related proteins by means of fret (fluorescence resonance energy transfer)
BR0317612A (en) Identification, monitoring and treatment of infectious disease and characterization of infectious disease-related inflammatory conditions employing gene expression profiles
FI990990A0 (en) Method for determination of disaccharidases and test kit for this

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP